Figure 2. Responses to treatment after
haploidentical-BMT. Shown are PET-CT images performed after each
respective treatment (Post-Rx). Post-Dx mo. indicate months after
initial diagnosis. (A) disease progression after haplo-BMT; (B) mixed
response with decreased mediastinal and chest wall FDG avidity but new
focal subpleural avid areas, new mildly avid pulmonary nodules and a new
focal lesion in the hepatic dome during second cycle of blinatumomab
(Blina) and following DLI but before progression to grade III GvHD; (C)
sustained tumor response with intense FDG uptake throughout the small
and large colon compatible with intestinal graft versus host disease
while on tapering doses of prednisone and cyclosporine A; (D) complete
metabolic response with less intestinal FDG uptake but evidence of
esophangitis and gastritis after discontinuing immunosuppression; (E)
disease recurrence after stopping blinatumomab and resolution of GvHD